FRIDAY, April 25, 2025 (HealthDay News) -- On Tuesday, the U.S. Department of Health and Human Services announced that the ...

Nearly a year and a half after Covid vaccines became available to adults in the U.S., the FDA has authorized two vaccines for ...

Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

Moderna (NasdaqGS:MRNA) experienced a 10% share price increase, coinciding with broader market gains but slightly below the Nasdaq Composite's 5% rise. Despite the market being uplifted by strong ...

The latest trading day saw Moderna (MRNA) settling at $27.19, representing a -0.75% change from its previous close.

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

BofA lowered the firm’s price target on Moderna (MRNA) to $26 from $32 and keeps an Underperform rating on the shares. For 2025, the firm’s ...

Federal regulators have asked Novavax to complete an additional clinical trial on its COVID-19 vaccine after previously ...

Bernstein lowered the firm’s price target on Moderna (MRNA) to $28 from $39 given recent political headwinds for the stock, while keeping a ...

Novavax faces a setback as the FDA requests an additional trial for COVID-19 vaccine approval. Read more here.

South Korean vaccine developer SK bioscience has won a final ruling in a patent dispute with Moderna (Nasdaq: MRNA) over key ...

Novavax's COVID-19 vaccine could soon receive full approval from the U.S. Food and Drug Administration (FDA), the company ...